​

ZyVersa Therapeutics Stock (NASDAQ:ZVSA)

RevenueFinancialsChart
ZyVersa Therapeutics by TradingView

Previous Close

$0.13

52W Range

$0.11 - $1.95

50D Avg

$0.15

200D Avg

$0.45

Market Cap

$1.10M

Avg Vol (3M)

$41.89K

Beta

0.83

Div Yield

-

ZVSA Company Profile

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

7

IPO Date

Feb 11, 2022

Website

ZVSA Performance

ZVSA Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-9.14B$-14.42M$-13.01M
Net Income$-9.41B$-98.30M$-759.10M
EBITDA$-9.14B$-107.74M$-11.67M
Basic EPS$-848.03$-1.09K$-930.25
Diluted EPS$-848.03$-1.09K$-930.25

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
XAGELongevity Health Holdings Inc.
WORXSCWorx Corp.
JSPRJasper Therapeutics, Inc.
CDTCDT Equity Inc.
ONCOOnconetix, Inc.
SLXNSilexion Therapeutics Ltd.
INDPIndaptus Therapeutics, Inc.
NIVFNewGenIvf Group Limited
ENVBEnveric Biosciences, Inc.